Rezdiffra (resmetirom), a newly FDA-approved treatment for NASH, functions as a thyroid hormone receptor beta (THR-β) agonist, which is thought to aid in reducing liver fat and improving fibrosis in NASH patients (Harrison et al., 2024). The gene discussed is THRB; the disease is metabolic dysfunction-associated steatohepatitis.